This study aims to present the manifestations of juvenile systemic lupus erythematosus (JSLE) across Egypt, to focus on age at onset and gender-driven influence on disease characteristics, and to compare findings to other countries.
Methods
The study included 404 Egyptian children with systemic lupus erythematosus (SLE) presenting to one of the specialized rheumatology centers corresponding to 13 major governorates. Juvenile cases age was ≤ 16°years at the time of recruitment. The SLE Disease Activity Index (SLEDAI) and damage index (DI) were assessed.
Results
The mean age was 13.2 ± 2.4°years; 355 females and 49 males (7.2:1), and the disease duration was 2.3 ± 1.6 years, while age at disease onset was 11.1 ± 2.5°years. Their SLEDAI was 13.5 ± 12.3, and DI, 0.36 ± 0.78. The overall estimated prevalence of childhood-SLE patients in the recruited cohort in Egypt was 1/100,000 population (0.24/100000 males and 1.8/100000 females). 7.4% developed pre-pubertal SLE (≤ 7 years); 73.3%, peri-pubertal; and 19.3% during early adolescence. The differences according to age group were equal for gender and clinical manifestations except skin lesions present in 59.3% of pre-pubertal onset, 74.6% of peri-pubertal, and 84.2% of adolescents (p = 0.029), and renal involvement in 73.8% of peripubertal, 62.1% of pre-pubertal and 58.9% of adolescents (p = 0.03). Laboratory investigations, SLEDAI, and DI were similar among age categories. Lupus nephritis was more common in Egypt compared to JSLE from other countries.
Conclusion
Our large multicenter study identified that female gender influenced disease characteristics with more frequent skin involvement. Skin lesions were significantly higher in adolescents, while renal involvement in peri-pubertal children.
TarrTDérfalviBGyőriN, et al.Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus2015; 24(8): 796–803. DOI: 10.1177/0961203314563817.
2.
AringerMCostenbaderKDaikhD, et al.2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol2019; 71(9): 1400–1412. DOI: 10.1002/art.40930.
3.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64(8): 2677–2686. DOI: 10.1002/art.34473.
4.
SmithEMDRasulSCiurtinC, et al.Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?-observations from the UK JSLE cohort study. Rheumatology2021. DOI: 10.1093/rheumatology/keab210.
5.
BatuEDAkcaUKKısaarslanAP, et al.The performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 classification criteria in pediatric systemic lupus erythematosus. J Rheumatol2021; 48(6): 907–914. DOI: 10.3899/jrheum.200871.
6.
MassiasJSSmithEMDAl-AbadiE, et al.Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus2020; 29(5): 474–481. DOI: 10.1177/0961203320909156.
7.
CharrasASmithEHedrichCM. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep2021; 23(3): 20. DOI: 10.1007/s11926-021-00985-0.
8.
SmithEMDLythgoeHMidgleyA, et al.Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol2019; 209: 108274. DOI: 10.1016/j.clim.2019.108274.
9.
OniLWrightRDMarksS, et al.Kidney outcomes for children with lupus nephritis. Pediatr Nephrol2021; 36(6): 1377–1385. DOI: 10.1007/s00467-020-04686-1.
10.
PusongchaiTJungthirapanichJKhositsethS. Pediatric systemic lupus erythematosus in Thammasat University hospital. J Med Assoc Thai2010; 93(Suppl 7): S283–S293.
11.
MassiasJSSmithEMAl-AbadiE, et al.Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus2021; 30(4): 597–607. DOI: 10.1177/0961203320984251.
12.
GheitaTAFawzySMNour El-dinAM, et al.Juvenile and adult onset systemic lupus erythematosus outcome in Egyptian patients. Egypt Rheumatol2011; 33(2): 99–105. DOI: 10.1016/j.ejr.2011.03.006.
BombardierCGladmanDDUrowitzMB, et al.Derivation of the sledai. A disease activity index for lupus patients. Arthritis Rheum1992; 35(6): 630–640.
15.
GladmanDDUrowitzMBGoldsmithCH, et al.The reliability of the systemic lupus international collaborating clinics/American college of rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum1997; 40(5): 809–813. DOI: 10.1002/art.1780400506.
16.
BajemaIMWilhelmusSAlpersCE, et al.Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int2018; 93(4): 789–796. DOI: 10.1016/j.kint.2017.11.023.
17.
Unicef. Egypt 2018: Statistical Abstract. Egypt: Central Agency for Public Mobilization and Statistics (CAPMAS). 2018, June(71-01113-2018).
18.
BahabriSAl SabbanEAl RashedA, et al.Juvenile systemic lupus erythematosus in 60 Saudi children. Ann Saudi Med1997; 17(6): 612–615. DOI: 10.5144/0256-4947.1997.612.
19.
Tavangar-RadFZiaeeVMoradinejadMH, et al.Morbidity and mortality in iranian children with juvenile systemic lupus erythematosus. Iranian J Pediatr2014; 24(4): 365–370.
20.
BuckleyMMRabinovichCE. Pulmonary manifestations of rheumatic diseases in children. Pediatr Clin North America2021; 68(1): 147–166. DOI: 10.1016/j.pcl.2020.09.005.
21.
AbdwaniRHiraMAl-NabhaniD, et al.Juvenile systemic lupus erythematosus in the sultanate of oman: clinical and immunological comparison between familial and non-familial cases. Lupus2011; 20(3): 315–319. DOI: 10.1177/0961203310383299.
22.
HirakiLTBenselerSMTyrrellPN, et al.Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr2008; 152(4): 550–556. DOI: 10.1016/j.jpeds.2007.09.019.
23.
Ramírez GómezLUribe UribeOOsio UribeO, et al.Childhood systemic lupus erythematosus in latin America. The GLADEL experience in 230 children. Lupus2008; 17(6): 596–604. DOI: 10.1177/0961203307088006.
24.
GheitaTANoorRAAbualfadlE, et al.Adult systemic lupus erythematosus in Egypt: the nation-wide spectrum of 3661 patients and world-wide standpoint. Lupus2021; 30: 1526–1535. DOI: 10.1177/09612033211014253.
25.
KamphuisSSilvermanED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol2010; 6(9): 538–546. DOI: 10.1038/nrrheum.2010.121.
HuangJLYaoTCSeeLC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol2004; 22(6): 776–80.
28.
BandeiraMBurattiSBartoliM, et al.Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus2006; 15(8): 515–520. DOI: 10.1191/0961203306lu2316oa.
29.
Torrente-SegarraVSalman monteTCRúa-FigueroaI, et al.Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: cluster analyses in a large cohort from the Spanish society of rheumatology lupus registry (RELESSER). Semin Arthritis Rheum2019; 48(6): 1025–1029. DOI: 10.1016/j.semarthrit.2018.09.005.
30.
DedeogluRŞahinSKokaA, et al.Evaluation of cardiac functions in juvenile systemic lupus erythematosus with two-dimensional speckle tracking echocardiography. Clin Rheumatol2016; 35(8): 1967–1975. DOI: 10.1007/s10067-016-3289-7.
31.
SönmezHEKarhanANBatuED, et al.Gastrointestinal system manifestations in juvenile systemic lupus erythematosus. Clin Rheumatol2017; 36(7): 1521–1526. DOI: 10.1007/s10067-017-3571-3.
32.
HayworthJLTurkMANevskayaT, et al.The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. Joint Bone Spine2019; 86(6): 685–690. DOI: 10.1016/j.jbspin.2019.06.001.
33.
KhajezadehMAZamaniGMoazzamiB, et al.Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus. Neurol Res Int2018; 2018: 2548142. DOI: 10.1155/2018/2548142.
34.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4(2): 295–306. DOI: 10.1111/j.1538-7836.2006.01753.x.
35.
GattornoMBuoncompagniAMolinariAC, et al.Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome. Rheumatology1995; 34(9): 873–881. DOI: 10.1093/rheumatology/34.9.873.
36.
El-GarfKEl-GarfAGheithR, et al.A comparative study between the disease characteristics in adult-onset and childhood-onset systemic lupus erythematosus in Egyptian patients attending a large university hospital. Lupus2021; 30(2): 211–218. DOI: 10.1177/0961203320972778.
37.
SahinSAdrovicABarutK, et al.Juvenile systemic lupus erythematosus in Turkey: demographic, clinical and laboratory features with disease activity and outcome. Lupus2018; 27(3): 514–519. DOI: 10.1177/0961203317747717.
38.
BalciSEkinciRMKBayazitAK, et al.Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey. Clin Rheumatol2019; 38(5): 1459–1468. DOI: 10.1007/s10067-019-04433-4.
39.
Al-MayoufSM. Systemic lupus erythematosus in Saudi children: long-term outcomes. Int J Rheum Dis2013; 16(1): 56–60. DOI: 10.1111/1756-185x.12020.
40.
LopesSRMGormezanoNWSGomesRC, et al.Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups. Lupus2017; 26(9): 996–1001. DOI: 10.1177/0961203317690616.
41.
GomesRCSilvaMFKozuK, et al.Features of 847 childhood-onset systemic lupus erythematosus patients in three age groups at diagnosis: a Brazilian multicenter study. Arthritis Care Res2016; 68(11): 1736–1741. DOI: 10.1002/acr.22881.
42.
AggarwalAPhatakSSrivastavaP, et al.Outcomes in juvenile onset lupus: single center cohort from a developing country. Lupus2018; 27(11): 1867–1875. DOI: 10.1177/0961203318791046.
43.
Al-MosawiZAl-HermiBEAl-SaadKK, et al.Juvenile systemic lupus erythematosus in Bahrain. A tertiary referral center experience. Saudi Med J2009; 30(5): 667–72.
44.
Martínez-BarrioJOvalles-BonillaJGLópez-LongoFJ, et al.Juvenile, adult and late-onset systemic lupus erythematosus: a long term follow-up study from a geographic and ethnically homogeneous population. Clin Exp Rheumatol2015; 33(6): 788–94.
45.
CabralMEscobarCCondeM, et al.Juvenile systemic lupus erythematosus in Portugal: clinical and immunological patterns of disease expression in a cohort of 56 patients. Acta Reumatol Port2013; 38(4): 274–285.
46.
RyggMPistorioARavelliA, et al.A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis2012; 71(4): 511–517. DOI: 10.1136/annrheumdis-2011-200106.
47.
WatsonLBeresfordMWMaynesC, et al.The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus2015; 24(1): 10–17. DOI: 10.1177/0961203314547793.
48.
Artim-EsenBŞahinSÇeneE, et al.Comparison of disease characteristics, organ damage, and survival in patients with juvenile-onset and adult-onset systemic lupus erythematosus in a combined cohort from 2 tertiary centers in turkey. J Rheumatol2017; 44(5): 619–625. DOI: 10.3899/jrheum.160340.
49.
TanJHTHohSFWinMTM, et al.Childhood-onset systemic lupus erythematosus in Singapore: clinical phenotypes, disease activity, damage, and autoantibody profiles. Lupus2015; 24(9): 998–1005. DOI: 10.1177/0961203315584413.
50.
AdelowoOOOlaosebikanBHAnimashaunBA, et al.Juvenile systemic lupus erythematosus in Nigeria. Lupus2017; 26(3): 329–333. DOI: 10.1177/0961203316672927.
